Posted: 28 January 2016 | Victoria White, Digital Content Producer, Drug Target Review | 1 comment
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
From innovative nanobombs that could potentially deliver agents direct to cancer cells, to the use of Big Data to unlock new targets for influenza, 2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
In October, the news broke that scientists had made an unexpected breakthrough – in their hunt for a weapon to fight malaria in pregnant woman, they discovered that armed malaria proteins can kill cancer. The carbohydrate that the malaria parasite attaches itself to in the placenta of pregnant women is identical to a carbohydrate found in cancer cells. The scientists managed to recreate the protein that the malaria parasite uses to adhere to the placenta and then they added a toxin. This combination of malaria protein and toxin sought out the cancer cells, was absorbed, the toxin released inside, and then the cancer cells died.
Earlier in the year, researchers revealed how the H7N9 influenza virus hides from the immune system, explaining why candidate vaccines have failed to elicit a strong immune response necessary to protect from infection. The researchers showed that the H7N9 haemagglutinin (HA) surface protein has evolved a set of mutations that make it similar to human protein. These mutations appear to effectively camouflage the pathogen from the immune system.
We went bananas for the story of BanLec. BanLec is a substance originally found in bananas that, when carefully edited by scientists, could someday fight off a wide range of viruses. Six years ago, it was shown that the compound could prevent the virus that causes AIDS from getting into cells – but it also caused side effects that limited its potential use. However, now scientists have created a new form of BanLec that still fights viruses in mice, but does not have the property that causes irritation and unwanted inflammation.
Late in 2015, researchers revealed that they had developed nanoparticles that swell and burst when exposed to near-infrared light. The researchers say the particles, dubbed ‘nanobombs’, could potentially change the face of cancer drug delivery as they can overcome a biological barrier that has blocked development of agents that work by altering the expression of genes in cancer cells.
Scientists from UC San Francisco revealing a chemical that could potentially be used in eye drops to reverse cataracts was another top story of 2015. The scientists tested ‘compound 29’ in an eye-drop formulation in mice carrying mutations that make them predisposed to cataracts. They found that the drops partially restored transparency to mouse lenses affected by cataracts. Similar results were seen when compound 29 eye drops were applied in mice that naturally developed age-related cataracts, and also when the compound was applied to human lens tissue affected by cataracts that had been removed during surgery.
In October, University of Nottingham researchers broke the news of their genetic discovery on how prostate cancer spreads. They identified a significant gene called miR137 that is switched off in prostate cancer cells. The loss of miR137 leads to enhanced androgen signalling which contributes to prostate cancer initiation and progression. The researchers’ study has identified many new potential targets for the next generation of drugs to treat prostate cancer.
Also in 2015, a team led by Christine Petit of the Institut Pasteur‘s Genetics & Physiology of Hearing Unit discovered the function of pejvakin, a molecule that plays a vital role in the hearing system. The absence of this molecule appears to be responsible for noise-induced hearing loss, one of the most common causes of deafness. The scientists now plan to look into possible techniques to restore the function of pejvakin, particularly using gene therapy, which has already proved successful in conserving hearing in mice lacking in pejvakin.
Another gene-related story makes our top 2015 list – gene therapy was shown to preserve vision in a study involving dogs with naturally occurring retinitis pigmentosa (RP). Even in dogs with later-stage disease, such therapy halted the loss of retinal thickness and preserved the structure of surviving photoreceptors. The findings contribute to the groundwork needed to move the therapy forward into clinical trials for people with the blinding eye disorder.
Antibiotics and antimicrobial resistance continue to be hot topics. In September, scientists from Virginia Tech made known their discovery of a new group of antibiotics that target Staphylococcus aureus and the antibiotic resistant strains commonly known as MRSA. The potential new antibiotics are unlike contemporary antibiotics because they contain iridium, a silvery-white transition metal. The researchers showed that the antibiotics effectively kill bacteria without inhibiting mammalian cells, despite containing the metal.
Last but not least, a recent story that has made it to our list is the December news that researchers from the Icahn School of Medicine at Mount Sinai tapped into publically available large-scale ‘Omics’ databases to identify new targets to treat influenza. By integrating multiple influenza A virus (IAV) host-pathogen ‘Omics’ databases, the team identified 20 previously unrecognised host proteins required for IAV replication. The study reflects a breakthrough approach using advanced computational designs to identify new factors that can be targeted to prevent viruses from spreading.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as "Necessary" are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies "Advertising & Targeting", "Analytics" and "Performance", these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to 'Enabled' or 'Disabled', then click 'Save and Accept'. View our Cookie Policy page.
Necessary cookies enable the core functionality of the website, including security, network management and accessibility. These cookies do not store any personal information. You may disable these by changing your browser settings, but this may affect how the website functions.
Cookie
Type
Duration
Description
cookielawinfo-checkbox-advertising-targeting
persistent
1 year
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
persistent
1 year
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
persistent
1 year
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
persistent
1 year
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
session
1 year
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
persistent
1 year
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
session
1 year
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Type
Duration
Description
advanced_ads_browser_width
persistent
1 month
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
persistent
2 years
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
persistent
1 month
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
persistent
1 year
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
persistent
2 years
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
persistent
2 years
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
persistent
3 months
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
persistent
1 month
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
persistent
5 months
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Type
Duration
Description
bcookie
persistent
2 years
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
persistent
30 minutes
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
session
1 year
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
persistent
1 day
This cookie is set by LinkedIn and used for routing.
lissc
persistent
11 months
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
persistent
2 years
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
persistent
2 years
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
persistent
20 minutes
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
persistent
20 minutes
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
persistent
20 minutes
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
persistent
2 years
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
persistent
1 minute
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
persistent
1 day
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Performance cookies include cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Type
Duration
Description
cf_ob_info
persistent
1 minute
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
persistent
1 minute
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
session
1 year
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
persistent
1 month
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
persistent
Until cleared
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
session
1 year
This cookie is set by Youtube and is used to track the views of embedded videos.
Excellent reports